JP2021518170A5 - - Google Patents
Info
- Publication number
- JP2021518170A5 JP2021518170A5 JP2021500367A JP2021500367A JP2021518170A5 JP 2021518170 A5 JP2021518170 A5 JP 2021518170A5 JP 2021500367 A JP2021500367 A JP 2021500367A JP 2021500367 A JP2021500367 A JP 2021500367A JP 2021518170 A5 JP2021518170 A5 JP 2021518170A5
- Authority
- JP
- Japan
- Prior art keywords
- hgfr
- human
- antibody fragment
- fusion protein
- extracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000003875 | 2018-03-22 | ||
| IT102018000003875A IT201800003875A1 (it) | 2018-03-22 | 2018-03-22 | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| PCT/IB2019/052307 WO2019180658A1 (en) | 2018-03-22 | 2019-03-21 | Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518170A JP2021518170A (ja) | 2021-08-02 |
| JP2021518170A5 true JP2021518170A5 (enExample) | 2022-02-22 |
| JP7381555B2 JP7381555B2 (ja) | 2023-11-15 |
Family
ID=62530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500367A Active JP7381555B2 (ja) | 2018-03-22 | 2019-03-21 | 腫瘍および／または転移の治療のための抗－ｈｇｆｒ抗体およびｈｅｇｆｒの組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11814433B2 (enExample) |
| EP (1) | EP3768710A1 (enExample) |
| JP (1) | JP7381555B2 (enExample) |
| KR (1) | KR20200135449A (enExample) |
| CN (1) | CN112041340A (enExample) |
| AU (1) | AU2019240274B2 (enExample) |
| BR (1) | BR112020018981A8 (enExample) |
| CA (1) | CA3093513A1 (enExample) |
| IL (1) | IL277476B1 (enExample) |
| IT (1) | IT201800003875A1 (enExample) |
| MX (1) | MX2020009787A (enExample) |
| SG (1) | SG11202008612XA (enExample) |
| WO (1) | WO2019180658A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3413363B1 (en) * | 2016-02-02 | 2021-03-24 | National Institute for Materials Science | Ferromagnetic tunnel junction, magnetoresistive effect element and spintronics device in which said ferromagnetic tunnel junction is used, and method of manufacturing ferromagnetic tunnel junction |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025188676A1 (en) * | 2024-03-04 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of cells for secretion of therapeutic antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1959955T3 (pl) * | 2005-12-05 | 2011-04-29 | Pfizer Prod Inc | Sposób traktowania nieprawidłowego wzrostu komórek |
| ES2368864T3 (es) * | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| CN101914161B (zh) * | 2010-08-13 | 2013-12-11 | 四川大学 | 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途 |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
-
2018
- 2018-03-22 IT IT102018000003875A patent/IT201800003875A1/it unknown
-
2019
- 2019-03-21 KR KR1020207030214A patent/KR20200135449A/ko active Pending
- 2019-03-21 CA CA3093513A patent/CA3093513A1/en active Pending
- 2019-03-21 EP EP19721054.5A patent/EP3768710A1/en active Pending
- 2019-03-21 SG SG11202008612XA patent/SG11202008612XA/en unknown
- 2019-03-21 US US16/982,330 patent/US11814433B2/en active Active
- 2019-03-21 WO PCT/IB2019/052307 patent/WO2019180658A1/en not_active Ceased
- 2019-03-21 MX MX2020009787A patent/MX2020009787A/es unknown
- 2019-03-21 JP JP2021500367A patent/JP7381555B2/ja active Active
- 2019-03-21 CN CN201980020753.XA patent/CN112041340A/zh active Pending
- 2019-03-21 BR BR112020018981A patent/BR112020018981A8/pt unknown
- 2019-03-21 AU AU2019240274A patent/AU2019240274B2/en active Active
-
2020
- 2020-09-21 IL IL277476A patent/IL277476B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE47860E1 (en) | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs | |
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| ES2902901T3 (es) | Anticuerpos de unión a APRIL modificados | |
| CA2999237C (en) | Novel anti-mesothelin antibody and composition comprising the same | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| ES2963561T3 (es) | Anticuerpo de unión a PSMA y usos del mismo | |
| US11623963B2 (en) | Cysteine engineered antigen-binding molecules | |
| JP2018512175A5 (enExample) | ||
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2021518170A5 (enExample) | ||
| WO2023109888A1 (zh) | 抗ang2-vegf双特异性抗体及其用途 | |
| JP2019511457A5 (enExample) | ||
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JP2022504392A5 (enExample) | ||
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| WO2025140522A1 (en) | Anti-tfr1 antibodies, preparation methods and uses thereof | |
| RU2020129465A (ru) | Комбинация антитела против hgfr и hegfr для лечения опухоли и/или метастаза | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| KR20260005269A (ko) | c-Met를 표적으로 하는 다중 특이성 항체 | |
| WO2026086844A1 (zh) | 靶向EGFR和c-Met的抗体药物偶联物 | |
| WO2025108427A1 (zh) | 结合分子及抗体药物偶联物和用途 | |
| WO2026067489A1 (zh) | ITGβ6结合蛋白及其用途 | |
| HK40119169A (zh) | 配体-细胞毒性药物偶联物及其药物用途 | |
| HK40084724A (en) | Engineered anti-her2 bispecific proteins |